Profile Solutions, Inc. (OTCPK: PSIQ)
Health Care · Pharmaceuticals · US
$0.00
— today · 0.0% 1Y
Profile Solutions, Inc. (OTCPK: PSIQ) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $777.00 and employs 5 people.
Over the last twelve months the share price has gained 0.0%, trading between 0.00 and 0.00.
Tweenvest scores Profile Solutions, Inc. across four factors: quality 39/100, value 51/100. Its strongest factor is value.
PSIQ price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $777.00
- Revenue (TTM)
- $770.21K
- P/E
- —
- EPS
- -0.00
- Dividend yield
- —
- Beta (5Y)
- 126.36
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 776.59M
- Employees
- 5
- Next earnings
- —
About Profile Solutions, Inc.
Profile Solutions, Inc., operating through its subsidiary, Elite Products International, Inc., specializes in the manufacturing and distribution of extracts derived from cannabinoid hemp. Their product line includes various forms such as ingestible items, topical creams, oils, and balms. The company offers a wide selection of edibles, including candies, gummies, cookies, "crystal pops," honey, and multivitamin supplements. Additionally, their inventory features oils, tinctures, vape products, and topical creams and salves. A notable offering is their dedicated range of creams and salves developed for household pets. The firm's corporate headquarters are situated in Sunrise, Florida.
- ISIN
- US74317L1061
- Listed since
- Nov 21, 2007
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.